Research Library

The human papillomavirus (HPV) affects over 80 million Americans, causing more than 40,000 cases of HPV-associated cancers in the U.S. In 2006, the FDA licensed the first HPV vaccine, which could help save thousands of lives; no cure for HPV currently exists. However, the political controversy raised by the vaccine has limited its acceptance and use. Such resistance potentially jeopardizes an opportunity to reduce cancer rates in Texas and the broader United States.

Stem cells from umbilical cord blood (CB) can be used to treat over 80 different diseases, including many types of leukemia, lymphoma and inherited immune system disorders. Extensive storage facilities in the United States and around the world collect, test and freeze CB for later use in medical procedures. However, the divide between two different banking models — public versus private — presents policy challenges. This policy report examines the difference between public and private cord blood banks and offers recommendations for US policymakers to improve cord blood banking and ensure high quality standards.

The Supreme Court handed down a 5-4 ruling on the Burwell v. Hobby Lobby case Monday, allowing some for-profit companies to opt out of paying for certain contraceptives for their employees. Elena Marks, president and CEO of the Episcopal Health Foundation and Baker Institute nonresident fellow in health policy, offered her insights on the ruling and how it will impact implementation of the Affordable Care Act, women’s access to reproductive care and future court cases.

Many contemporary medical ethicists dismiss the centuries-old Hippocratic Oath as outdated because of the enormous scientific, social, economic, and political changes since Hippocrates' time. Health policy scholar Hagop Kantarjian makes a case for its relevance.

In a genuine effort to protect patients from adverse events, regulatory burdens and research rigidity in clinical trials have increased to a point at which such protection is outweighing the benefits, and actually harming patients who are unable to be involved in clinical trials.

Kirstin Matthews, fellow in science and technology, answers questions regarding the biology, practical uses and ethical dilemmas surrounding stem cells.